2013-01-16 06:59:17 -

BB BIOTECH AG /
BB Biotech AG earns after-tax profits of CHF 368 million in fiscal 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

In   accordance   with  regulations  on  ad  hoc  publicity,  BB  Biotech  (ISIN
CH0038389992) is releasing the following information about its profits in fiscal
2012.

Based  on preliminary unaudited consolidated results, BB Biotech closed the past
year  with a profit of CHF 368 million  (loss of CHF 146 million in the previous
year).  After  three  very  strong  quarters  with  profits  in the triple-digit
millions, general profit-taking in the market towards the end   of the year led to
a loss of CHF 134 million for the quarter.

The  net profit figure for 2012 reflects the fundamental strength of the biotech
sector and the successful investment strategy pursued by BB Biotech with clearly
defined  areas of focus. BB Biotech's share price rose 42.7% in CHF and 42.9% in
EUR during the past year.

Portfolio holdings as of December 31, 2012 will be reported on January
24, 2013. The annual report for 2012 will be published on February 21, 2013.




For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 09, teg@bellevue.ch
www.bbbiotech.com




Company profile

BB  Biotech invests in companies in the fast growing market of biotechnology and
is  one of the  world's largest investors  in this sector  with approx. CHF 1.2
billion in assets under management. BB Biotech is listed in Switzerland, Germany
and  Italy. Its investments are focused  on listed companies that are developing
and  commercializing novel medical treatments and cures. BB Biotech's investment
selection  process  is  guided  by  the  fundamental  research  and  analysis of
physicians  and molecular biologists.  Its Board of  Directors has many years of
experience in industry and science.

Media Release (PDF): 
 hugin.info/130285/R/1670622/542937.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: BB BIOTECH AG via Thomson Reuters ONE
[HUG#1670622]